At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 79 enrolled
Drug / intervention
tiotropium bromide +1 moredrug
Likely dose
tiotropium bromide 18 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-controlled, Double-blind, Parallel Group, Multi Center Study to Assess the Safety and Efficacy of Tiotropium Bromide (18 µg) Delivered Via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) Subjects Recovering From Hospitalization for an Acute Exacerbation (Hospital Discharge Study 1)
In Brief
A Phase 4 clinical trial evaluating tiotropium bromide and Placebo for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 79 participants across 50 sites in 2 countries.
Detailed Summary
A randomized, placebo-controlled, double-blind, parallel group, multi center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) subjects recovering from hospitalization for an acute exacerbation (Hospital Discharge 1)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2012
First PostedAug 2012
Primary CompletionMay 2014
TodayJul 2026
First PostedAug 14, 2012
Enrollment StartAug 1, 2012
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.9 years ago
Interventions
tiotropium bromidedrug
18 mcg once a day (QD)
Placebodrug
once a day (QD)